Pfizer Starts Mid-Stage Trial for Vaccine against Omicron Subvariant

Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified COVID-19 vaccine that targets both the original as well as the BA.2 omicron subvariant.

Pfizer said the vaccine is in an initial proof-of-concept study to gather more data.

Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95% of the circulating coronavirus variants in the United States for the week ended Jul 23._Reuters